Incidence of Abnormal Cervical and Vaginal Cytology among Women over Age 65 Living with Human Immunodeficiency Virus.
Women with human immunodeficiency virus (HIV) have higher rates of abnormal cervical and vaginal cytology and, subsequently, of cervical and vaginal cancers. While professional bodies currently advocate for indefinite cytology screening for women living with HIV, these recommendations are based on expert opinion, not evidence-based. In the general population, women who have never had an abnormal cytology result can cease screening at age 65. This is due to the relatively low incidence of dysplasia in this group and the risk of false-positive results as women age, invasive follow-up testing, and destructive treatments of lesions that are unlikely to progress to cancer. What is unclear, however, is how HIV-infected women over age 65 who have no history of abnormal cytology should be screened in order to maximize benefit while reducing harms of over-screening. This is a crucial question, as women over age 65 living with HIV is a rapidly growing population. To describe the incidence of abnormal cervical and vaginal cytology results in women living with human immunodeficiency virus over age 65, with the goal of providing evidence for screening recommendations. A retrospective chart review was performed, identifying 69 women who received gynecologic follow up in a county hospital system in Houston, TX between 2000 to 2018 and met study criteria. Incidence of abnormal cytology after age 65 was determined by analyzing all available cytology results after age 65. Demographic and clinical risk factors, including HIV-specific clinical risk factors, were analyzed. Matched cervical and vaginal pathology results, if conducted, were also evaluated. Statistical analyses were conducted using Stata 15, including X2 tests and Wilcoxon rank-sum tests for categorical and continuous variables, respectively. Estimates of the cumulative probability of developing an abnormal cytology result was calculated using the Kaplan-Meier method. Among 69 women with no history of abnormal cervical cytology, 12 (17%) went on to develop abnormal cytology results, including 3 (4%) showing high-grade squamous intraepithelial lesions. Incidence rate was 3.5 cases per 100 woman-years (95% CI: 1.58, 7.81). No demographic or gynecologic characteristics were associated with abnormal cytology. A CD4 count <200 at time of HIV diagnosis or at time of cytology was associated with an abnormal Pap (p<0.0001, p=0.031). Of women with pathology results in the county hospital system (n=8), 4 (50%) had CIN2+ or VAIN2+. No women developed invasive cancer. However, 50% of women who had an abnormal Pap test in the study period were lost to follow up; outcomes for these patients are unknown. Given the relatively high proportion (4%) of women with HSIL/CIN 2+/VAIN 2+ during the study period, we agree with current screening recommendations for continued routine Pap testing after the age of 65 in women with HIV. More evidence from larger studies is needed to solidify evidence-based screening recommendations in this unique and growing population.